All In Biotech

Drug Trial Radar · NCT06806137

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Dec 14, 2026

Study completion May 3, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.

Conditions

  • Chickenpox

Interventions

  • Investigational varicella vaccineBiological

    Investigational varicella vaccine administered subcutaneously.

  • Marketed varicella vaccineBiological

    Marketed varicella vaccine administered subcutaneously.

  • MMR vaccineBiological

    MMR vaccine co-administered subcutaneously or intramuscularly.

  • Hepatitis A vaccineBiological

    Hepatitis A vaccine co-administered intramuscularly.

  • PCV (pneumococcal conjugate vaccine) 13Biological

    The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • PCV 20Biological

    The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

  • VaxneuvanceBiological

    The Vaxneuvance (15-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti- glycoprotein E (gE) IgG for 2 doses of VNS vaccine compared to 2 doses of VVTime frame: At Day 133 (43 days post-dose 2)
  2. Geometric Mean Concentration (GMC) of anti-VZV gE IgG for 2 doses of VNS vaccine compared to 2 doses of VVTime frame: At Day 133 (within 43 days post-dose 2)

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Constanza, Dominican Republic · Recruiting

  • GSK Investigational Site

    Santo Domingo Oeste, Dominican Republic · Recruiting

  • GSK Investigational Site

    Salvaleón de Higüey, La Altagracia Province, Dominican Republic · Recruiting

  • GSK Investigational Site

    San Pedro Sula, Honduras · Recruiting

  • GSK Investigational Site

    Tegucigalpa, Honduras · Recruiting

  • GSK Investigational Site

    Tegucigalpa, Honduras · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.